über einen geplanten Vortrag Schendels für einen Kongress in Boston an Bedeutung.
Der Anspruch von Schendel ist es, die Lücken bei der Sicherheit der CAR-T Therapie mittels Medigenes adoptiver T-Zelltherapie zu schließen. Die neuste Entwicklung bei Juno zeigt den Bedarf an größerer Sicherheit bei den zellulären Immuntherapien (Target-Selektivität auch bei Kombitherapien). Mir scheint Medigenes Ansatz bei der Sicherheit so manchem Wettbewerber überlegen. Nun müssen Medigenes Studien diese Hypothese bestätigen.
Hier noch einmal ein wesentlicher Auszug des Posts von Richy, der in diesem Forum gänzlich kommentarlos zur Kenntnis genommen wurde:
ADOPTIVE T-CELL THERAPY SUMMIT 2016 AGENDA
Mind the gap and fill the need: TCR cell therapies for patients with different MHCs and diverse forms of cancer Benchmarking adoptive T cell therapies by the success of CD19-specific CAR T cell therapies for B cell malignancies, taking into account lingering B cell deficiencies in many clinical responders. A major gap is apparent if one looks beyond this success, due to limitations in surface antigens that can be used to target tumor cells without potentially causing damage to vital healthy tissues. TCR cell therapies hold the potential to fill this gap for both hematological cancers and solid tumors by their capacity to target tumor cells through an enormous variety of intracellular proteins, even including patient-specific neoantigens. Using high-throughput and state-of-the-art technologies to prime T cells de novo to rapidly acquire optimal affinity TCRs specific for widely diverse intracellular proteins. The identified and isolated TCRs recognize specific epitopes presented by various HLA allotypes.
By our proprietory technologies we are able to tailor TCRs for different patient groups, filling the gap for TCR therapies for MHC divergent patient populations suffering from diverse forms of cancer. The use high-throughput platform technologies to acquire T cells specific for any selected combination of intracellular tumor-associated/specific antigen and HLA allotype.
Bypassing the need for pre-existing T cells responses in patients, giving us maximum flexibility to acquire TCRs of any desired specificity.Technologies yield natural TCR sequences that display optimal functional avidity upon expression in T cells, without need for mutagenesis to improve TCR affinity.
TCR platform embodies state-of-the-art tools to assess TCR specificity, safety and pre-clinical efficacy using a combination of in silico, in vitro and ex vivo assessments.
Establishing automated approaches for rapid and efficient screening processes, opening the door to capture TCRs of individual patients specific for neoantigens.
Efficiently identify antigens and epitopes seen by T cells that reside in some patients and display tumor specificity. Access to TCRs of such T cells opens additional avenues of adoptive immunotherapy.
Hier noch ein Auszug von DJS aus der Brochure des geplanten CAR-TCR Summit 2016 in Boston:
The ABC’s of Adoptive T Cell Therapy Using Optimal Affinity Natural TCRs Specific for Hematological Malignancies and Solid Tumors
It is critical to consider three ABC’s in the selection of TCR therapy candidates based on the TCR itself and its target ligand.
- A: Feasibility of TCR gene therapy for many patients with different types of malignancy depends on having a library of TCRs that can recognize appropriate MHC-restricted peptide ligands matched to the needs of an individual patient
- B: Safety is coupled to TCR fine specificity and comprehensive evaluation is needed to preclude
potential on- and off-target toxicities as far as possible before first-in-man use
- C: Efficacy of TCR gene therapy is coupled to functional avidity and persistence of therapeutic T cells in vivo.
TCR selection and choice of recipient T cell populations can be combined to provide therapeutics of potential better efficacy.
Examples of approaches applying these ABC’s of TCR gene therapy will be presented and discussed. Dolores Schendel, CEO/CSO, Medigene
|
Thread abonnieren
